State of The Art Treatment for Hepatitis C
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Overview
Since 2001, combination therapy with pegylated interferon with ribavirin is considered the standard of care in hepatitis C treatment. In clinical trials, 50 to 60 percent of patients treated with combination therapy achieved a sustained virologic response, or SVR, meaning the virus is undetectable in their blood. Dr. Jorge Herrera joins host Dr. Leslie Lundt to discuss the state of the art for treatment of Hepatitis C.
Recommended
Details
Presenters
Overview
Since 2001, combination therapy with pegylated interferon with ribavirin is considered the standard of care in hepatitis C treatment. In clinical trials, 50 to 60 percent of patients treated with combination therapy achieved a sustained virologic response, or SVR, meaning the virus is undetectable in their blood. Dr. Jorge Herrera joins host Dr. Leslie Lundt to discuss the state of the art for treatment of Hepatitis C.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?